The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Sodium–Glucose Cotransporter-2 Inhibitors and the Risk for Diabetic Ketoacidosis: A Multicenter Cohort Study
Abstract
BACKGROUND: Sodium-glucose cotransporter-2 (SGLT-2) inhibitors could increase the risk for diabetic ketoacidosis (DKA). OBJECTIVE: To assess whether SGLT-2 inhibitors, compared with dipeptidyl peptidase-4 (DPP-4) inhibitors, are associated with an increased risk for DKA in patients with type 2 diabetes. DESIGN: Population-based cohort study; prevalent new-user design between 2013 and 2018. (ClinicalTrials.gov: NCT04017221). SETTING: Electronic health care databases from 7 Canadian provinces and the United Kingdom. PATIENTS: 208 757 new users of SGLT-2 inhibitors were matched by using time-conditional propensity scores to 208 757 recipients of DPP-4 inhibitors. MEASUREMENTS: Cox proportional hazards models estimated site-specific hazard ratios (HRs) with 95% CIs of DKA comparing receipt of SGLT-2 inhibitors with receipt of DPP-4 inhibitors, which were pooled by using random-effects models. Secondary analyses were stratified by molecule, age, sex, and prior receipt of insulin. RESULTS: Overall, 521 patients were diagnosed with DKA during 370 454 person-years of follow-up (incidence rate per 1000 person-years, 1.40 [95% CI, 1.29 to 1.53]). Compared with DPP-4 inhibitors, SGLT-2 inhibitors were associated with an increased risk for DKA (incidence rate, 2.03 [CI, 1.83 to 2.25] versus 0.75 [CI, 0.63 to 0.89], respectively; HR, 2.85 [CI, 1.99 to 4.08]). Molecule-specific HRs were 1.86 (CI, 1.11 to 3.10) for dapagliflozin, 2.52 (CI, 1.23 to 5.14) for empagliflozin, and 3.58 (CI, 2.13 to 6.03) for canagliflozin. Age and sex did not modify the association; prior receipt of insulin appeared to decrease the risk. LIMITATIONS: There was unmeasured confounding and no laboratory data were available for the majority of patients, and molecule-specific analyses were conducted at a limited number of sites. CONCLUSION: SGLT-2 inhibitors were associated with an almost 3-fold increased risk for DKA, with molecule-specific analyses suggesting a class effect. PRIMARY FUNDING SOURCE: Canadian Institutes of Health Research.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Neal, B., Perkovic, V., Mahaffey, K. W., de Zeeuw, D., Fulcher, G., Erondu, N., Shaw, W., Law, G., Desai, M., & Matthews, D. R. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1611925 · Cited by 7,830
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
Wiviott, S. D., Raz, I., Bonaca, M. P., Mosenzon, O., Kato, E. T., Cahn, A., Silverman, M. G., Zelniker, T. A., Kuder, J. F., Murphy, S. A., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1812389 · Cited by 6,382
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
Perkovic, V., Jardine, M. J., Neal, B., Bompoint, S., Heerspink, H. J. L., Charytan, D. M., Edwards, R., Agarwal, R., Bakris, G., Bull, S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1811744 · Cited by 6,189
Austin, P. C. (2011) · Pharmaceutical Statistics · doi:10.1002/pst.433 · Cited by 3,949 · cited 1×
“2 SD of the TCPS on the logarithmic scale (Supplement Table 1) (16).”
BackgroundZelniker, T. A., Wiviott, S. D., Raz, I., Im, K., Goodrich, E. L., Bonaca, M. P., Mosenzon, O., Kato, E. T., Cahn, A., Furtado, R. H. M., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(18)32590-x · Cited by 2,845
Data Resource Profile: Clinical Practice Research Datalink (CPRD)
Herrett, E., Gallagher, A. M., Bhaskaran, K., Forbes, H., Mathur, R., van Staa, T., & Smeeth, L. (2015) · International Journal of Epidemiology · doi:10.1093/ije/dyv098 · Cited by 2,667 · cited 11×
“inces (Alberta, British Columbia, Manitoba, Nova Scotia, Ontario, Quebec, and Saskatchewan) and a primary care clinical database from the United Kingdom, the Clinical Practice Research Datalink (CPRD) (14), which was linked to the Hospital Episode Statistics and Office for National Statistics databases.”
MethodInfluentialEvaluating medication effects outside of clinical trials: new-user designs
Ray, W. A. (2003) · American Journal of Epidemiology · doi:10.1093/aje/kwg231 · Cited by 1,646
Tamez-Pérez, H. E. (2015) · World Journal of Diabetes · doi:10.4239/wjd.v6.i8.1073 · Cited by 387
Risk of diabetic ketoacidosis after initiation of an SGLT2 inhibitor
Fralick, M., Schneeweiss, S., & Patorno, E. (2017) · New England Journal of Medicine · doi:10.1056/nejmc1701990 · Cited by 334 · cited 2×
“Some studies had methodological limitations (9, 11), whereas others included mostly younger patients (8, 12), and only 1 study was powered to provide molecule-specific estimates (11).”
BackgroundResultSelf-citation
Cited by
Yang, D.-R., Wang, M.-Y., Zhang, C.-L., & Wang, Y. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1359255 · Cited by 280
Euglycemic diabetic ketoacidosis: etiologies, evaluation, and management
Long, B., Lentz, S., Koyfman, A., & Gottlieb, M. (2021) · The American Journal of Emergency Medicine · doi:10.1016/j.ajem.2021.02.015 · Cited by 150
Lin, D. S.-H., Lee, J.-K., & Chen, W.-J. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab274 · Cited by 97
Colacci, M., Fralick, J., Odutayo, A., & Fralick, M. (2022) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2021.04.006 · Cited by 94
Self-citationSGLT-2 inhibitors associated euglycemic and hyperglycemic DKA in a multicentric cohort
Ata, F., Yousaf, Z., Khan, A. A., Razok, A., Akram, J., Ali, E. A. H., Abdalhadi, A., Ibrahim, D. A., Al Mohanadi, D. H. S. H., & Danjuma, M. I. (2021) · Scientific Reports · doi:10.1038/s41598-021-89752-w · Cited by 87
Metadata
- Authors
- Douros, A., Lix, L. M., Fralick, M., Dell'Aniello, S., Shah, B. R., Ronksley, P. E., Tremblay, É., Hu, N., Alessi-Severini, S., Fisher, A., Bugden, S. C., Ernst, P., & Filion, K. B.
- Venue
- Annals of Internal Medicine
- Publisher
- American College of Physicians
- Published
- 2020-09-15
- Volume
- 173
- Issue
- 6
- Pages
- 417-425
- ISSN
- 0003-4819 (ISSN-L)
- 1539-3704
- OpenAlex
- W3046159964
- Cited by
- 184
- References
- 10
- FWCI
- 14.97
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Sodium–Glucose Cotransporter-2 Inhibitors and the Risk for Diabetic Ketoacidosis: A Multicenter Cohort Study. https://app.cochat.ai/papers/10.7326/m20-0289
- The paper
- Douros, A., Lix, L. M., Fralick, M., Dell'Aniello, S., Shah, B. R., Ronksley, P. E., Tremblay, É., Hu, N., Alessi-Severini, S., Fisher, A., Bugden, S. C., Ernst, P., & Filion, K. B. (2020). Sodium–Glucose Cotransporter-2 Inhibitors and the Risk for Diabetic Ketoacidosis: A Multicenter Cohort Study. Annals of Internal Medicine. https://doi.org/10.7326/m20-0289
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.